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Abstract The WWOX gene is a tumour suppressor gene
affected in various types of malignancies. Numerous
studies showed either loss or reduction of the WWOX
expression in variety of tumours, including breast, ovary,
liver, stomach and pancreas. Recent study demonstrated
that breast cancer patients exhibiting higher WWOX
expression showed significantly longer disease-free surviv-
al in contrast to the group with lower relative WWOX level.
This work was undertaken to show whether similar
phenomena take place in colon tumours and cell lines. To
assess the correlation of WWOX gene expression with
prognosis and cancer recurrence in 99 colorectal cancer
patients, we performed qRT-PCR analysis. We also per-
formed analysis of WWOX promoter methylation status
using MethylScreen method and analysis of loss of
heterozygosity (LOH) status at two WWOX-related loci,
previously shown to be frequently deleted in various types
of tumours. A significantly better disease-free survival was
observed among patients with tumours exhibiting high level
of WWOX (hazard ratio=0.39; p=0.0452; Mantel–Cox log-
rank test), but in multivariate analysis it was not an
independent prognostic factor. We also found that although
in colorectal cancer WWOX expression varies among
patients and correlates with DFS, the exact mode of
decrease in this type of tumour was not found. We failed
to find the evidence of LOH in WWOX region, or hyper-
methylation in promoter regions of this gene. Although we
provide the evidence for tumour-suppressive role of WWOX
gene expression in colon, we were unable to identify the
molecular mechanism responsible for this.
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Introduction
The WWOX (WW domain containing oxidoreductase) gene
is located in the chromosome 16 region 16q23.3–24.1, also
known as common fragile site FRA16D [1], an area which
was found to be frequently affected by allelic losses in
breast and other cancers [2]. WWOX expression was
reported to be higher in the testis, ovary and prostate, i.e.
tissues where its activity is regulated hormonally [1]. On
this basis, WWOX was speculated to be involved in
regulation of the steroids signalling pathways. Studies on
biological role of WWOX in tumourigenesis showed that its
function in cellular metabolism is likely to modulate gene
expression by interactions with other proteins involved in
cell cycle/apoptosis control and transcription factors. Up to
now several partner proteins were identified, i.e. p73, AP-
2γ[3], ErbB-4 [4], Runx2 [5] and members of Dvl protein
family [6]. It was also shown that WWOX protein
physically binds to two cytoplasmic regions of ErbB-4,
which were previously verified to be responsible for
interactions with Yap proteins. This competition for the
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and may lead to dysregulation of cell signalling [4].
Regardless of its function in cell metabolism, WWOX is
considered as a tumour suppressor gene in various types of
malignancies, including: breast [7], ovarian and lung cancer
[2]. The evidence for its tumour suppressor activity was
demonstrated for the first time in several cancer cell lines
[7]. Since then numerous studies showed either loss or
reduction of the WWOX expression in a variety of human
tumours of breast, ovary, liver, stomach, pancreas, oesoph-
agus, lung and haematopoietic malignancies [8]. Latest
studies showed that WWOX gene is a bona fide tumour
suppressor gene (reviewed in [3]), however the most
common mechanism of decreasing WWOX expression in
cancer cells is through hemizygous deletions (especially in
breast cancer), while point mutations are very rare [1].
Recently, a set of complex deletions was found at FRA16D
in the HCT116 colon cancer cell line, which was
responsible for removing fragments of WWOX gene [9].
Another mechanism of reducing WWOX transcriptional
level which was vastly studied is CpG islands hyper-
methylation of WWOX promoter and coding region. It
seems that this mechanism may play some role in down-
regulation of WWOX expression in several cancer cell lines,
for example tumours of pancreas and prostrate [10], breast,
lung and bladder [11]; however first reports on methylation
at the WWOX promoter region in thirteen breast cancer cell
lines revealed that despite dramatic difference in WWOX
expression, there was no methylation present at this region
in any studied cell line [7]. Płuciennik et al. have shown
that breast cancer patients exhibiting higher levels of
WWOX expression exhibited significantly longer DFS in
contrast to the group with relatively lower WWOX transcript
levels [12]. Similarly, Aqeilan et al. showed prognostic
relevance of WWOX and ErbB4 proteins in breast cancer
[13].
With all results cited above, the lack of studies
regarding role of WWOX gene and its protein product in
tumourigenesis in colon and especially homozygous
deletions in WWOX r e g i o nf o u n di nH C T 1 1 6c o l o nc a n c e r
cell line, as reported by [9], prompted us to undertake
present work. The aim of our research was to evaluate the
role of deletions in WWOX gene, its expression and
prognostic value in patients with CRC (colorectal cancer).
We also evaluated methylation of WWOX gene promoter
region and the correlations of WWOX expression level
with other well-known cancer/cell cycle-related genes, as:
pro-apoptotic BAX, anti-apoptotic BCL2,c e l lc y c l er e g u -
lators: cyclins D1 (CCND1)a n dE 1( CCNE1)b o t h
regarded as playing an important role in tumourigenesis,
tumour suppressor gene TP73 which encodes for the p73
protein, proliferation marker - Ki-67 and one ERBB4
isoform transcript—JM-a/CVT-1.
Materials and methods
Patients and samples
The CRC samples analysed herein were obtained from 99
cases of primary colorectal tumours treated at the Oncology
Clinic, Medical University of Łódź. Only patients without
previous familial history of CRC and those who did not
receive preoperative radiotherapy were enrolled to this
study. From these, only 50 had complete history of disease
and reliable DFS observations (thus only these patients
could be included to survival analysis). Experiments
involving human subjects were conducted according to
the Declaration of Helsinki: the study was approved by the
Ethics Committee at Medical University of Łódź. The mean
age of the patients was 61.3 years (median, 63 years; for
women, 60 years; for men, 63 years; range, 30–86 years).
Median follow-up period was 42.5 months. More detailed
characteristics of the patients are shown in Table 1, together
with WWOX mRNA level and results of Mann–Whitney U
test. Tumours were classified according to the International
Union Against Cancer staging and grading criteria. The
tissue samples were examined histologically and stored at
−80°C in RNAlater (Ambion, Inc.) until RNA extraction.
Cancer cell lines
We used cell lines derived from tumours of colon (HCT116,
SW480, SW620, HT-29) and two breast cancer cell lines
(MDA-MB-231, MCF-7), which served as a control of our
results, as both were previously studied for WWOX
expression [7, 14]. Cell culture was performed according
to the vendor's protocol. In brief, HT-29 and HTC116 cell
lines were grown in McCoy's 5a medium with addition of
1% L-Glutamine; SW480 and SW620 were cultured in
RPMI1640; MCF-7 and MDA-MB-231 cell lines were
cultured in DMEM Advanced Medium with 1% L-
Glutamine; MCF-7 cells were also supplemented with
addition of bovine insulin to the final concentration
0.01 mg/ml. All media were supplemented with 10% foetal
bovine serum and 1% PSN antibiotic mixture (penicillin,
streptomycinandneomycin;allingredientsSigma,Germany).
Atmosphere consisted of 95% of air and 5% of CO2;
incubation temperature was 37°C.
Real-time quantitative RT-PCR analysis
All RNA extractions and cDNA synthesis were performed
as described elsewhere [12]. All real-time RT-PCR reac-
tions were performed in duplicate, except the samples in
which the analysis outcome was questionable. If this had
happened, another two replicates were analysed. Detection
of the amplification product was enabled with EvaGreen®
552 Tumor Biol. (2011) 32:551–560dye (Biotium Inc., Hayward CA, USA), according to the
manufacturer's recommendations in Corbett Research RG-
3000 platform (Corbett Life Science, Sydney, Australia), in
total reaction volume of 10 or 25 μl. Expression levels were
normalised using the panel of four genes: β2-microglobulin
B2M, histone H3F3A, ribosomal proteins RPS17 and
RPLP0, which were selected using the geNorm applet [15].
Relative expression was calculated with the mathematical
model allowing for correction of reaction efficiency and
using the Universal Human Reference RNA (Stratagene, La
Jolla, CA, USA) as a reference. Primer sequences used in
this study are shown in Table 2; detailed PCR protocols are
available upon request from the corresponding author.
LOH analysis
In order to determine the LOH status of the 16q23.3–24.1
region, we used two sequence-tagged site (STS) markers:
D16S3096 and D16S518. They are located at: eighth intron
and second intron, respectively, of WWOX gene. The
D16S518 marker is the most frequently affected with
LOH in breast cancer (up to 77% in some populations, as
described in [16]). Primer sequences used were according
to UniSTS database (http://www.ncbi.nlm.nih.gov/). HRM
analysis of ampilification products was performed in a
LightCycler 480 (Roche Diagnostics, Poland) with EpiTect
HRM PCR Kit (Qiagen, Germany).
Feature n WWOX mRNA median (range) P (Mann–Whitney U)
Sex
Women 51 1.49 (1.23–3.744) 0.3985
Men 48 1.51 (0.57–2.193)
Localisation of the primary tumour
a
Rectum 34
a 1.69 (0.29–3.74) 0.8301
Sigmoid colon 37
a 1.42 (1.23–2.47)
Descending colon 6
a
Splenic flexure 3
Transverse colon 4
Ascending colon 3
Cecum 14
Lymphocytic infiltration
Absent 57 1.68 (1.23–3.87) 0.1908
Present 41 1.35 (0.29–3.46)
Unknown 1
Metastasis to the lymph nodes
#
Absent 55 1.65 (1.24–4.26) 0.1591
Present 34 1.57 (0.57–3.52)
Unknown 10
Grading (differentiation)
G1 10 1.09 (0.01–21.38) 0.7331 (G1/G2)
G2 60 1.51 (1.24–3.66) 0.7643 (G2/G3)
G3 29 1.60 (0.57–4.26) 0.7153 (G1/G3)
Dukes' stage
A 26 1.119 (0.21–3.66) 0.6489 (A/B)
B 29 1.858 (0.32–4.78) 0.4133 (B/D)
C 26 2.475 (1.31–7.35) 0.8777 (A/C)
D 16 1.342 (0.86–4.89) 0.3166 (A/D)
Unknown 2
Relapse during follow-up
No 34 2.10 (0.97–5.729) 0.1008
Yes 27 1.32 (0.162–2.06)
Unknown 38
Demise during follow-up
No 46 2.10 (1.26–5.729) 0.2370
Yes 45 1.40 (0.57–2.475)
Unknown 8
Table 1 Correlations of WWOX
expression with clinical charac-
teristics of the patients
aThe localisation of primary
tumours from three patients was
ambiguous, thus they were
qualified to two groups
Tumor Biol. (2011) 32:551–560 553Analysis of WWOX methylation status
To assess the methylation status of one 5′-upstream region
involved in regulation of WWOX expression (from −508 to
−174 bp) and region adjacent to and containing WWOX
promoter (from −171 to +239 bp) we used novel bisulfite-
free alternative technology MethylScreen, utilising the real-
time quantitative PCR assay on templates generated by
combined restriction digest using: methylation-sensitive
restriction enzymes (MSRE), methylation-dependent restric-
tion enzymes (MDRE), combined double digest (both MSRE
and MDRE) and mock digestion [17]. The enzymes used in
this study were: HhaI, HpaII (MSRE) and McrBC (MDRE;
New England Biolabs, Ipswich, MA, USA); all digestions
were performed according to the manufacturer's instructions
on 500 ng of patient's DNA. All PCRs were performed in
total volume of 50 μl, with 4 μl of respective digested
sample DNA, 1 μl of each primer (10 mM). The sequences
of the primers used were as follows: −508 bp region; For—
5′-ACAGAAGCCCAGGACAACAGCATGG-3′;R e v —5′-
ACCACGAAGCTGAAATCCAGTCTCCG-3′; −171-bp
region; For—5′-AGACTGGATTTCAGCTTCGTGGTCG-
3′;R e v —5′-AAGCTCCTTAACAGTTACTTTCACTTTG
CAC-3. Cycle conditions were: 95°C for 5 min followed
by 55 cycles of 94°C for 30 s, 55°C/30 s, 72°C/90 s and 77°
C/15 s (fragment −508 bp) or 95°C for 5 min followed by 50
cycles of 94°C for 30 s, 50°C/30 s, 72°C/90 s and 80°C/15 s
(fragment −171 bp).
Statistical analysis
Spearman's rank correlation test was used to analyse possible
linear associations between all the gene expression levels.
Disease-free survival was estimated with the Kaplan–Meier
method. The significance of differences between survival
rates was verified using the log-rank (Mantel–Cox) test.
Disease-free survival was calculated according to Kaplan–
Meier method. Multivariate survival analysis was performed
using Cox's regression model. Values of p<0.05(confidence
level>95%) were considered statistically significant.
Table 2 Real-time RT-PCR primers and reaction conditions used for expression analysis of specified genes
Gene name Gene primers (For/Rev) Annealing
temperature (°C)
Detection
temperature (°C)
PCR product size
(bp) (5′→3′)
BAX For: AGAGGTCTTTTTCCGAGTGGCAGC 56 81 137
Rev: TTCTGATCAGTTCCGGCACCTTG
BCL2 For: TTGGCCCCCGTTGCTTTTCCTC 56 81 122
Rev: TCCCACTCGTAGCCCCTCTGCGAC
B2M For: TGAGTGCTGTCTCCATGTTTGA 50 81 88
Rev: TCTGCTCCCCACCTCTAAGTTG
CCND1 For: GTCCTACTACCGCCTCACACGCTTCCTCTCCAG 63 86 160
Rev: TCCTCTTCCTCCTCCTCGGCGGCCTTG
CCNE1 For: TTCTTGAGCAACACCCTCTTCTGCAGCC 68 68 138
Rev: TCGCCATATACCGGTCAAAGAAATCTTGTGCC
ERBB2 For: TGACCTGCTGGAAAAGGGGGAGCG 63 83 150
Rev: TCCCTGGCCATGCGGGAGAATTCAG
ERBB4 For: ACACAGCCCTCCTCCTGCCTACAC 56 76 95
Rev: AGGGCACAGACACTCCTTGTTCAGC
H3F3A For: AGGACTTTAAAACAGATCTGCGCTTCCAGAG 65 72 76
Rev: ACCAGATAGGCCTCACTTGCCTCCTGC
Ki-67 For: TCCTTTGGTGGGCACCTAAGACCTG 56 81 156
Rev: TGATGGTTGAGGCTGTTCCTTGATG
RPLP0 For: ACGGATTACACCTTCCCACTTGCTGAAAAGGTC 65 72 69
Rev: AGCCACAAAGGCAGATGGATCAGCCAAG
RPS17 For: AAGCGCGTGTGCGAGGAGATCG 64 72 87
Rev: TCGCTTCATCAGATGCGTGACATAACCTG
TP73 For: AACCACGAGCTCGGGAGGGACTTCAAC 63 81 159
Rev: TTCCGTCCCCACCTGTGGTGGCTC
WWOX For: GAGCTGCACCGTCGCCTCTCCCCAC 63 77 150
Rev: TCCCTGTTGCATGGACTTGGTGAAAGGC
For, forward primer; Rev, reverse primer
554 Tumor Biol. (2011) 32:551–560Results
Correlation of WWOX expression with clinical parameters
Relative WWOX expression in CRC tissues ranged from 0
to 123.18 (median 7.66). Results of statistical analysis of
WWOX expression in groups of patients divided according
to the classical clinical markers are presented in Table 1.
We did not find any statistically significant relations
between groups of patients stratified according to their
basic clinicopathological features; however, we found a
tendency for higher relative WWOX expression in samples
from patients without relapse during the follow-up period
(2.10 versus 1.32 units; p=0.1008). This finding was then
confirmed by analysis of DFS based on relatively high and
low WWOX expression, which showed significant differ-
ences. The cut-off point for discrimination between ‘high’
and ‘low’ expression of WWOX was 2.70 (units of relative
expression). This point was selected with the X-tile
software [18]. We found that this cut-off value applied to
the standard Kaplan–Meier DFS analysis yielded a signif-
icantly better DFS observed among patients with tumours
in which the level of WWOX mRNA was classified as high
(hazard ratio; HR=0.39; p=0.0452; Cox–Mantel log-rank
test; Fig. 1), however in multivariate analysis it was not an
independent prognostic factor (p=0.8027). We also con-
ducted survival analysis of patients stratified according to
the localisation of primary tumour. Although we found
disparity between DFS in patients with primary tumour
localised in rectum versus all other localisations, this was
not statistically significant (HR=0.48; p=0.1566).
Analysis of WWOX expression in cell lines
HCT116 colon cancer cell line, although previously found
to harbour homozygous deletion in WWOX gene, surpris-
ingly showed 70% level of WWOX expression, in compar-
ison with MCF-7 cells (all results in Table 3). Reason for
this results is suggested by the work of Alsop et al. [9];
authors imply that HCT116 homozygous deletions are
within WWOX intron, so they should not affect its
expression (apart for the supposed role of WWOX Δ6–
8 transcript in decreasing WWOXwt transcription, which
nowadays is not supported by solid evidence). Indeed, they
previously found two WWOX transcripts: variant 1
(WWOXwt) and variant 4 (WWOX Δ6–8) in this cell line
[2], although Northern blots presented showed that
WWOXwt appears in low abundance. This discrepancy
could be in part linked to different techniques used, as
suggested by Ding et al.: the correlation between the
Northern and qRT/PCR results for 24 genes studied was r=
0.39; after excluding outlier genes the correlation coeffi-
cient rised to 0.72, still far from ideal [19]. We also found
that HT-29 cell line, originating from a colorectal adeno-
carcinoma, showed very low level of WWOX expression.
The difference in WWOX expression between SW480 and
SW620 cell lines suggest that there is a room for stating
that WWOX has some role (not fully identified yet) in the
progression of CRC tumours: SW480 cells, originating
from primary tumour showed 0.230 of WWOX relative
expression; whereas in SW620 cells, from metastatic
tumour of the same patient, relative WWOX expression
was even lower, 0.175. This result is similar to the
difference in WWOX relative expression among patients
with lymph node metastases and patients in which there
was no nodal metastasis present (1.65 vs. 1.57), however
that relationship was not statistically significant (p=
Fig. 1 Results of DFS analysis in patients stratified according to the
WWOX mRNA level (Kaplan–Meier test)
Table 3 WWOX expression in the studied cell lines
Cell lines Average WWOX relative expression
HCT116 1.075
HT29 0.080
SW480 0.230
SW620 0.175
MCF-7 1.497
MDA-MB-231 0.025
Tumor Biol. (2011) 32:551–560 5550.1591). MCF7 cells showed the highest expression of the
studied cell lines; accordingly, aggressive and highly
metastatic breast cancer cell line MDA-MB-231 had the
lowest WWOX expression (60-fold lower than MCF-7),
which is in accordance with previous reports [2, 3].
Analysis of methylation and LOH status of WWOX gene
locus
In the studied population of patients, we did not find any
significant hemizygosity suggesting LOH at the investigat-
ed loci in CRC tumours samples. Cell lines exhibited
differences in surveyed markers (Table 4), however this had
no connection to the expression level of WWOX. For
instance SW620 cells, which showed retention of both
alleles as the only one cell line studied, exhibited almost
tenfold lower WWOX expression than MCF-7 cells, which
expression was the highest observed here.
There was no significant methylation of WWOX promoter
in patients' samples: we found that only eight (8.1%) of
patients had low methylation and two (2%) had moderate
methylation at 5′-upstream region (−508 to −174 bp),
whereas only seven (7.1%) of patients exhibited low
methylation at region adjacent to and containing WWOX
promoter (from −171 to +239 bp). Of the patients, 12.1%
had non-informative results of analysis at 5′ upstream region,
while at the promoter region the number of non-informative
cases was 8.1% (all results in Table 5). None of the cell lines
used in this study showed methylation of WWOX promoter
region (data not shown). Statistical analysis of correlations
between methylation level or LOH at studied loci and
WWOX relative expression did not prove that there was any
relationship between those parameters in our study.
Correlation of WWOX transcript level with expression
of other genes
We found that WWOX wt expression is correlated (with
statistical significance; Spearman rank correlation test used)
with number of surveyed genes (presented in order of
lowering probability): significant negative correlation with
CCNE1 expression (−0.3579; p=0.0005), which in general
is regarded as a marker of bad prognosis and is directly
associated with tumourigenesis. We also found a significant
positive correlation with BCL2/BAX ratio (0.3480; p=
0.0006). Positive correlations were found between WWOX
expression and ERBB4 and BCL2 (all results in Table 6).
Discussion
In the presented study, we analysed the expression of
WWOX gene in 99 tumours from patients with colorectal
cancer. In several reports it was shown that WWOX
expression is lowered in various types of tumours (men-
tioned above). Moreover, many authors have shown that
suppressed transcription of WWOX is associated with more
aggressive phenotype of breast cancer [12], non-small cell
lung cancer [20] and ovarian cancer [21]. Here, we show
that relatively high WWOX expression corresponds with
better disease-free survival of CRC patients hazard ratio
(HR=0.39; p=0.0452; Mantel–Cox log-rank Test, Fig. 1)i n
comparison with those with lowered WWOX transcription.
This supports the view that loss of WWOX expression is
associated with tumourigenesis in different types of
cancers. Such an idea was additionally proven by in vitro
and in vivo studies which showed that elevated WWOX
expression suppresses tumourigenicity of different cancer
cell lines: breast [7], lung [22] and prostate [23]. However,
WWOX expression cannot be used as an independent
prognostic marker in CRC, since results of multivariate
analysis excluded this marker from analysis on early stages
(results not shown). Despite the frequent suppression of
WWOX expression in many cancers, complete gene
inactivation by deletion of one allele and second mutation
or homozygous deletion is very rare [9]. Based on the
observations, it was postulated that WWOX inactivation is
driven by hemizygous deletions, which was recently proven
with mouse model using targeted deletion of WWOX gene
[24]. In our analysis of 16q23.3–24.1 region we did not
find any evidence for LOH in the two studied WWOX-
associated loci in CRC. We used two STS (sequence-tagged
site) markers (D16S3096 and D16S518) which are most
often afflicted by hemizygous deletions in all kinds of
cancers, for instance: breast ductal carcinoma in situ lesions
[16], breast cancer metastases [25], hepatocellular carcino-
ma [26], non-small cell lung cancer [27], oesophageal
squamous cell carcinoma [28], gastric carcinoma [29], but
none of the STS markers displayed LOH in our set of
colorectal cancer samples.
STS marker Cell lines
HCT116 HT-29 SW-480 SW-620 MCF-7 MDA-MB-231
D16S3096 R LOH R R LOH LOH
D16S518 LOH R LOH R LOH LOH
Table 4 LOH analysis in two
WWOX gene regions in human
cancer cell lines
LOH, loss of one allele; R,
retention of both alleles; NI,
non-informative result
556 Tumor Biol. (2011) 32:551–560We also tested the status of methylation in the promoter
region of WWOX gene, presumably resulting in lowered
WWOX expression, which was shown in several studies
[11, 22]. Nevertheless, there are data showing that the
methylation status of WWOX promoter region does not
contribute to the decrease of WWOX expression in breast
cancer cell lines and prostate tumours [7, 30] which is also
in the case of CRC patients studied herein. To our
knowledge, this is the first report on methylation status of
WWOX gene in CRC patients or CRC cell lines. Neverthe-
less, results of our MethylScreen analysis were very similar
to the previously cited work by Bastian et al. [30], who
analysed CpG island hypermethylation in a set of 13 gene
loci (including WWOX) in 78 prostate carcinomas, 32
benign prostate hyperplasias and four prostate cell lines
(LNCaP, DU145, PC3, BPH-1) using MethyLight PCR.
They found only one case showing WWOX promoter region
methylation; none of the benign samples were methylated
in WWOX locus [30]. Moreover, none of the cell lines
surveyed (LNCaP, DU145, PC3, BPH-1) exhibited meth-
ylation of WWOX [30]. Interestingly, previous studies
showed loss of WWOX expression in as much as 84% (37
of 44 tumour samples) [23] and involvement of promoter
methylation in decreasing of WWOX expression in prostate
cancer cell lines LNCaP, DU145 and PC-3 [23]. We
hypothesise that this striking discrepancy between the two
abovementioned papers could arise because of the two
different strategies of study: Bastian et al showed the exact
methylation status of WWOX by using MethyLight PCR,
whereas Qin et al. used methylation-specific PCR (MSP).
One should remember that MSP is gel-based technique and
provides rather qualitative results, whereas PCR-based
techniques are able to discriminate between different levels
of methylation. Qin et al. also assumed that increased
WWOX mRNA and protein expression in prostate cancer-
derived cells after treatment with 5-aza-2′-deoxycytidine
(AZA; a DNA methyltransferase inhibitor) and trichostatin
A (a histone deacetylase inhibitor), is a result of demethy-
lation of only WWOX promoter region. However, one
should be aware of the fact that these agents are not specific
and they change the global methylation/acetylation status of
the cell, including all hypothetical and/or unknown regu-
lators of WWOX expression.
Recently, a paper by Kosla et al. showed that both
methylation of WWOX promoter region and LOH at
D16S518, D16S3096 and D16S504 have influence on
WWOX expression in glioblastoma multiforme tumours
[31]. In this work, we did not find any evidence for such a
relationship, which may suggest that these mechanisms are
tissue specific.
We found that in population of Polish patients studied
herein WWOX expression correlated with several genes
involved in cell cycle/apoptosis or interacting with WWOX.
The strongest correlation found was negative association of
WWOX expression level with that of CCNE1 (−0.3579; p=
0.0005). Cyclin E1 is thought to be a potential predictor of
systemic therapy, because of the cell cycle alterations
induced by its overexpression: decreased length of the G1
phase, faster transition from G1 to S phase and increased
genomic instability [32]. Moreover, overexpression of
CCNE1 and amplification in breast cancer human breast
epithelial cells results in chromosomal instability and worse
prognosis [32]. In colorectal cancer cells it was found that
combined treatment of these cells with various cytotoxic
drugs (e.g. c-myc antisense phosphorothioate oligonucleo-
tides, taxol, 5-fluorouracil (5-FU), doxorubicin and vin-
blastine) resulted in growth arrest of these cells in the G2/M
and S phases, noticeable apoptotic effect and the reduction
of mRNA levels of BCL2, BCLxL, CDK2, cyclin E1, CDK1
and cyclin B1, while increasing the mRNA levels of p21,
p27, BAX and caspase-3 [33].
We also found correlation of WWOX transcription level
with the BCL2/BAX expression ratio (0.3480 p=0.0006).
This relationship would mean that in CRC patients with
higher WWOX expression, the tumours/its cells are less
Table 5 Results of the WWOX promoter regions methylation analysis
in CRC patients
Methylation status Number of cases (%)
5′-Upstream region WWOX promoter region
(−508 to −174 bp) (−171 to +239 bp)
‘0’ 77 (77.8%) 84 (84.8%)
‘1’ 8 (8.1%) 7 (7.1%)
‘2’ 2 (2.0%) 0 (0%)
NI 12 (12.1%) 8 (8.1%)
Sum 99 99
‘0’, no methylation found (difference between the Mock and the
MDRE less than one cycle); ‘1’, low methylation (difference between
the Mock and the MDRE 1≥1.49 cycle); ‘2’, intermediate methylation
(difference between the Mock and the MDRE >1.5 cycle); NI, non-
informative result
Table 6 Correlations between WWOX wt expression and other genes
(Spearman test)
Gene name Spearman rank correlation coefficient p Value
CCNE1 −0.3579 0.0005
BCL2/BAX ratio 0.3480 0.0006
BAX/BCL2 ratio −0.3308 0.0012
Ki67 −0.2913 0.0046
ERBB4 0.2473 0.0242
BCL2 0.2066 0.0372
ERBB2 −0.1957 0.0709
BAX −0.1684 0.0906
Tumor Biol. (2011) 32:551–560 557prone to apoptosis. This seemingly paradoxical finding has
been also recently reported by Reeve's group in CRC
patients. The impact of tumour proliferation on the grade of
malignancy in CRC is not clear, especially when markers
well established for breast cancer are used (e.g. Ki-67,
PCNA) that is why the group used a self-devised colon-
specific gene-proliferation signature (GPS) [34], including
36 genes commonly expressed (upregulated) in an expo-
nentially growing in vitro CRC model and in human colon
proliferative crypt compartments. Among the GPS genes,
there are 15 cell cycle related, for instance CCNA2 (cyclin
A2), CDC2 (cell division cycle 2, G1 to S and G2 to M,
transcript variant 1). After stratification of colorectal
tumours into high and low GPS groups by K-means
clustering method, authors found that reduced GPS expres-
sion was associated with shorter DFS in CRC patients [34].
Authors also validated the GPS on public microarray data
from two independent breast cancer experiments and found
that in breast cancer group with increased GPS had
significantly shorter DFS [34]. It is worth mentioning that
among the 36 GPS genes there are only two involved in
apoptosis—MADL2, which is anti-apoptotic and ITGB3BP
(integrin beta 3 binding protein, NRIF3) shown to induce
rapid and profound apoptosis in various breast cancer cell
lines [35]. In a previous report, it was found that in breast
cancer patients, the median expression of WWOX was
almost 13-fold lower in tumours exhibiting BCL2/BAX ratio
lower than 2 [12]. Similarly, in the presented work:
colorectal tumours in which BCL2/BAX ratio was lower
than 2, showed WWOX median expression 0.791, whereas
in samples with higher BCL2/BAX ratio it was 4.590 (5.81-
fold difference; p=0.0025). We also hypothesise that
WWOX expression regulation in CRC, or in colon tissue/
cell lines in general, could be similar to the E-cadherin
(CDH1) gene/E-Cad protein. This well-known tumour
suppressor, which is located in the vicinity of WWOX locus
(16q22.1) was reported to have decreased expression in
various cancers, including CRC. However, the exact mode
of CDH1 expression regulation was largely unknown when
studies were performed to identify the ‘classical’ ways of
downregulating gene expression. Early works on down-
regulation of E-Cad expression due to the mutations in
CDH1 gene showed that the mutation rate in this gene was
low [36]. Also, polymorphisms found in the CDH1 and its
promoter region seems to have at least ambiguous
significance in regulation of E-Cad expression, because
studies on greater number of patients showed no such
associations [37]. Epigenetic changes (methylation status)
in CDH1 gene region in tumours were also studied, but
results of these analyses are also unclear and seem to
depend mostly on the technique used in the survey (this
situation is very much alike to the one of WWOX
methylation). Once again, when methylation was studied
using MSP-based methods, it seemed that this kind of
regulation has great influence on E-cad protein level [38],
whereas study done using the qPCR-based method
(MethyLight) showed extremely modest level of CDH1
promoter methylation and there was no correlation between
DNA methylation and E-cad protein level (neither in tumour
tissues nor the normal mucosae; total 142 pairs of matching
tissues) [39]. Also in a paper mentioned earlier, Bastian et al.
described differences between the CDH1 promoter methyl-
ation status they found in prostate carcinomas and previously
published results of such analyses in this kind of tumour
[30]. The next step in resolving this complexity was the
showing of different repressor proteins that contribute to E-
cad transcription regulation. Up to this date many of these
transacting factors were discovered, including: Snail, Slug,
Twist, SIP1/ZEB2, deltaEF1/ZEB2, as reviewed in [38].
Recently, a paper by Guler et al. described a relationship
between the “triple negative” breast tumours phenotype and
reduced expression of WWOX with elevated expression of
AP-2γ (as shown by using tissue microarrays), although the
authors did not find direct correlation between WWOX
neither AP-2α nor Ap-2γ expression levels [40]. In
summary, in this study we found that WWOX expression
varies among patients and correlates with DFS, however we
were unable to identify the molecular reason of lowered
WWOX transcription. Our data suggest that unlike other
tumours, WWOX expression in colorectal cancer is affected
by different mechanisms than small deletions or methylation
of promoter region. These findings, the ambiguous nature of
role of the WWOX promoter methylation in expression
regulation and the previous studies showing a wide array of
proteins interacting with WWOX (e.g. YAP, ErbB-4, Dvl
family) seem to suggest that there is a place to hypothesise
that phenomena similar to CDH1 expression regulation may
occur in WWOX expression regulation in colon.
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